CTXR - Citius Pharmaceuticals Inc logo

CTXR

Citius Pharmaceuticals Inc

Rev โ€”top 1%5Y
Hold

Citius Pharmaceuticals develops biopharmaceutical products targeting critical care. Key offerings include LYMPHIR for cutaneous T-cell lymphoma, Mino-Lok for catheter infections, Halo-Lido for hemorrhoid relief, and NoveCite for ARDS treatment.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 10 years ago โ†’$3today

Score Overview

1 Year
Scoreโ€”
Net Growth-23.42%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-99.79%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend20%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-344.88%
Net Trend22%
Net Income Consistency
Rev Growthโ€”
Rev Trend11%
Revenue Consistency

See the full market ranking โ†’

Citius Pharmaceuticals Inc fundamental performance

Across Citius Pharmaceuticals Inc's full reported history, from 2017 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 10M to -$ 37M. Revenue increased in 11% of the years measured; net income in 22%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.77โ€”
1 Year2025-08-12
$ 1.30-41.15%
5 Years2021-08-12
$ 46.25-98.35%
10 Years2016-08-12
$ 262.50-99.71%
All Time2017-07-06
$ 156.25-99.51%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 5M-$ 46M$ 4M
2025$ 0.00-$ 37M$ 4M
2024$ 0.00-$ 39M$ 3M
2023$ 0.00-$ 32M$ 26M
2022$ 0.00-$ 33M$ 41M
2021$ 0.00-$ 23M$ 70M
2020$ 0.00-$ 17M$ 13M
2019$ 0.00-$ 15M$ 7M
2018$ 0.00-$ 12M$ 9M
IPO2017$ 0.00-$ 10M$ 3M

Explore beyond CTXR

You're looking at Citius Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies